Pairwise Comparative Safety and Effectiveness of Anti-TNF Blockers, Vedolizumab, and Ustekinumab During Pregnancy: A Systematic Review and Meta-Analysis.

Dig Dis SciMay 25, 2026 (epub)
Clinical ResearchGastroenterologyObstetrics & GynecologyOpen access

Omotayo Segun-Omosehin, Natalie E Bourdakos, Kosta G Tzanis et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the safety and effectiveness of anti-TNF blockers, vedolizumab (VDZ), and ustekinumab (UST) during pregnancy in patients with inflammatory bowel disease (IBD). Analyzing data from nine observational studies involving 6,054 patients, the study found that VDZ was associated with a higher risk of preterm delivery (RR=1.35) and active disease (RR=1.55) compared to TNF blockers.

Key findings

  • VDZ was linked to a higher risk of preterm delivery (RR=1.35) compared to TNF blockers.
  • UST showed an increased risk of active disease (RR=1.30) and congenital anomalies (RR=2.08) compared to TNF blockers.
  • Compared to UST, VDZ was associated with higher risks of preterm birth (RR=2.60) and low birth weight (RR=2.38).

Why it matters

Understanding the comparative safety profiles of biologic therapies during pregnancy is crucial for managing inflammatory bowel disease. This information aids clinicians in making informed treatment decisions to balance disease control and maternal-fetal safety.

Source

PubMed · PMID 42183927Free full text on PubMed Central

Published in Dig Dis Sci. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.